Opus Genetics IRD Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -271.9%+293pp | -564.7%-509pp | -55.5%-101pp | 45.7%— | |
| Net margin | -349.3%+174pp | -523.4%-471pp | -52.4%-97.3pp | 44.9%— | |
| EBITDA margin | -271.5%+293pp | -564.6%-509pp | -55.4%-101pp | 45.7%— | |
| Returns | |||||
| Return on equity | -449.4%-246pp | -203.2%-182pp | -20.8%-73.0pp | 52.3%— | |
| Return on assets | -113.9%+12.8pp | -126.7%-107pp | -19.4%-67.1pp | 47.7%+307pp | |
| Efficiency | |||||
| Asset turnover | 0.3×+0.1× | 0.2×-0.1× | 0.4×-0.7× | 1.1×— | |
| Liquidity | |||||
| Current ratio | 6.4×+3.2× | 3.2×-10.1× | 13.3×-4.4× | 17.8×+11.0× | |
| Quick ratio | 6.4×+3.2× | 3.2×-10.1× | 13.3×-4.4× | 17.8×+11.0× | |
| Cash ratio | 5.8×+3.1× | 2.7×-9.8× | 12.5×-3.0× | 15.5×+9.1× | |
| Leverage | |||||
| Debt-to-equity | 0.1×— | —— | —— | —— | |
| Debt-to-assets | 0×— | —— | —— | —— | |
| Interest coverage | -299.2×— | —— | —— | 2,025.1×+13,378× | |
| Per Share | |||||
| Book value per share | $0.25-2.0% | $0.25-89.1% | $2.31+3.0% | $2.24+50.0% | |
| Valuation | |||||
| Market capitalization | $307.14M+442% | $37.57M— | —— | —— | |
| Enterprise value | $248.38M— | —— | —— | —— | |
| Price / sales | 25.6×+21.5× | 3.4×— | —— | —— | |
| Price / book | 9×+3.4× | 5.6×— | —— | —— | |
| EV / sales | 20.7×— | —— | —— | —— | |
| Earnings yield | -34.8%+68.6pp | -153.1%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Opus Genetics's ratios come from?
- Every ratio is computed from Opus Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
